Table 1. Patients’ clinical and demographic characteristics at baseline.
| Characteristic | Mean±SD or no. of cases (n=102) | Range |
|---|---|---|
| Sex (male-female) | 57-45 | - |
| Age (year) | 65.64±11.20 | 28-91 |
| Weight (kg) | 62.50±9.45 | 40.5-83 |
| Height (cm) | 167.0±7.43 | 150-186 |
| Smoking history (yes-no) | 71-31 | - |
| Pleural effusion (yes-no) | 55-47 | - |
| Tumor size (cm) | 4.34±1.64 | 1.4-10.1 |
| Tumor site (central-peripheral) | 42-60 | - |
| CEA (ng/mL) | 71.40±88.73 | 0.91-1005 |
| CA125 (U/mL) | 110.03±257.67 | 11.47-2482.1 |
| CA153 (U/mL) | 50.10±103.37 | 4.5-1016.2 |
| EGFR mutation (yes-no) | 17-31** | - |
| Previous treatments | ||
| Surgery (yes-no) | 7-95 | - |
| Local radiotherapy (yes-no) | 89-13 | - |
| Chemotherapy (yes-no) | 73-29 | - |
| EGFR inhibitor (yes-no) | 17-85 | - |
| Lymphocyte (%) | 18.01±8.68 | 3.3-44.5 |
| Brain metastases (yes-no) | 11-91 | - |
| Bone metastases (yes-no) | 35-67 | - |
| Tumor histology (SQ-AD) | 48-54 | - |
| ECOG PS (0/1/2-3) | 31-71 | - |
**
48 of 102 performed EGFR mutation analysis.